SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

DaVitas warning that Medicare reimbursement for CorMedixs lead product, DefenCath, could fall sharply in 2027 has fueled a steep selloff and concern about future pricing and revenue. Traders dispute how definitive DaVitas preliminary outlook is, pointing to CMSs published rate estimates and arguing that greater use could offset lower reimbursement.

Shopify, Inc. is a global commerce company that provides essential internet infrastructure for commerce, offering trusted tools to start, scale, market, and run a retail business of any size. The Company's software enables merchants to run their business across all of their sales channels, including web and mobile storefronts, physical retail locations, social media storefronts and marketplaces. The Shopify platform provides merchants with a single view of their business across all of their sales channels and enables them to manage products and inventory, process orders and payments, fulfill and ship orders, build customer relationships, source products, leverage analytics and reporting and access financing, all from one integrated back office. The company was founded on September 28, 2004 and is headquartered in Ottawa, Canada.

Shopify Inc - Ordinary Shares - Class A (Sub Voting)

Shopify Inc

Shopify is drawing attention ahead of its upcoming earnings, with traders debating whether growth will support the stock after a volatile pullback. Bullish traders expect a strong report, while others cite valuation and unverified concerns about security issues in third-party apps as reasons for caution.

Visa, Inc. engages in the provision of digital payment services. It also facilitates global commerce through the transfer of value and information among a global network of consumers, merchants, financial institutions, businesses, strategic partners, and government entities. It offers debit cards, credit cards, prepaid products, commercial payment solutions, and global automated teller machines. The company was founded by Dee Hock in 1958 and is headquartered in San Francisco, CA.

Visa Inc - Ordinary Shares - Class A

Visa Inc

Visas fiscal Q4 results are driving discussion: a modest earnings beat and resilient payment activity are tempered by a slower-growth outlook, prompting a sell-the-news reaction. Bulls point to durable consumer spending and cross-border activity, while skeptics argue the results and guidance fall short of expectations.

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

Inovios FDA approval of a competing RRP treatment has put pressure on Precigens PAPZIMEOS, prompting debate over how much competition could affect its sales. Traders are split: some see the rival as a serious threat, while others emphasize Precigens full approval and commercial head start, alongside questions about Inovios accelerated-approval requirements and ability to launch.

ProShares Trust - ProShares UltraPro QQQ 3x Shares

ProShares UltraPro QQQ

A sharp Nasdaq and tech-sector selloff has driven attention to TQQQ, with traders citing worries about AI spending and earnings alongside inflation, interest-rate, and geopolitical risks. The community is split between buying the steep dip for a possible rebound and warning that further losses may follow.

Hyperliquid Strategies, Inc. is a holding and operating company, which engages in the business of crypto asset management. The firm operates as a digital asset treasury company which focuses on the Hyperliquid ecosystem. The company was founded on July 2, 2025 and is headquartered in New York, NY.

Hyperliquid Strategies Inc.

PURR is drawing attention as a listed treasury proxy for Hyperliquids HYPE token, with traders linking its swings to HYPEs rally and the broader ecosystems growth. Bulls see room for a catch-up move or short squeeze, while bears point to share issuance and dilution as reasons PURR has lagged the token.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Eli Lillys strong quarterly results and raised revenue outlook, driven by demand for Mounjaro and Zepbound, are fueling a rally to record highs. Bulls point to continued growth in its obesity-drug franchise, while skeptics highlight the trimmed profit outlook, rich valuation, and weaker-than-expected Foundayo sales.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TGTX has climbed to a 52-week high as traders anticipate its Q3 results and continued BRIUMVI growth; some attribute the move to earnings expectations, while others speculate about a buyout or short covering. No acquisition has been confirmed, and the earnings date remains unconfirmed.

The Walt Disney Co. engages in the business of international family entertainment and media enterprise. It owns and operates television and radio production, distribution and broadcasting stations, direct-to-consumer services, amusement parks, and hotels. It operates through the following business segments: Disney Entertainment, ESPN, and Disney Parks, Experiences, and Products. The company was founded by Walter Elias Disney on October 16, 1923 and is headquartered in Burbank, CA.

Walt Disney Co (The)

Walt Disney Co

Better-than-expected quarterly results, led by strong parks performance and improving streaming profitability, have renewed optimism about Disneys turnaround under new leadership. Traders are debating whether those business trends can lift the stock after its muted, range-bound performance.

Internet Computer (ICP) is a cryptocurrency launched in 2021. Internet Computer has a current supply of 558,194,898.12638538. The last known price of Internet Computer is 2.5370221 USD and is up 5.18 over the last 24 hours. It is currently trading on 447 active market(s) with $63,762,762.22 traded over the last 24 hours. More information can be found at https://internetcomputer.org/.

Internet Computer

Discussion centers on ICPs sovereign-cloud and AI infrastructure ambitions, including posts about a Pakistan national chat app beta and potential government adoption. Bulls view these as signs of real-world utility, while skeptics point to weak adoption, token-supply concerns and prolonged underperformance.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Nuvation Bio to Expand Pivotal Phase 3 SIGMA Study of Safusidenib for IDH1-Mutant Glioma to Six European Countries

Nuvation Bio to Expand Pivotal Phase 3 SIGMA Study of Safusidenib for IDH1-Mutant Glioma to Six European Countries Nuvation Bio to Expand Pivotal Phase 3 SIGMA Study of Safusidenib for IDH1-Mutant Glioma to Six European CountriesPR NewswireNEW YORK, Oct. 29, 2026 New sites in the UK, France...

Nuvation Bio to Report Third Quarter 2026 Financial Results and Provide Business Update on November 4, 2026

Nuvation Bio to Report Third Quarter 2026 Financial Results and Provide Business Update on November 4, 2026 Nuvation Bio to Report Third Quarter 2026 Financial Results and Provide Business Update on November 4, 2026PR NewswireNEW YORK, Oct. 21, 2026 NEW YORK, Oct. 21, 2026 /PRNewswire/ -- Nuvation...

Why Is Nuvation Bio Stock Gaining Thursday?

Nuvation Bio (NUVB) stock jumps 6% after early FDA label update for IBTROZI, highlighting over 4 years of clinical benefit in ROS1+ NSCLC.read more...

Nuvation Bio Announces FDA Approval of Supplemental New Drug Application for IBTROZI (taletrectinib) with Updated Duration of Response in TKI-Nave Advanced ROS1-Positive Non-Small Cell Lung Cancer

Nuvation Bio Announces FDA Approval of Supplemental New Drug Application for IBTROZI (taletrectinib) with Updated Duration of Response in TKI-Nave Advanced ROS1-Positive Non-Small Cell Lung Cancer Nuvation Bio Announces FDA Approval of Supplemental New Drug Application for IBTROZI (taletrectinib...

Nuvation Bio Announces New Analyses Reinforcing the Durable, Consistent Efficacy of IBTROZI (taletrectinib) Across Key Patient Subgroups in Advanced ROS1+ NSCLC at 2026 World Conference on Lung Cancer

Nuvation Bio Announces New Analyses Reinforcing the Durable, Consistent Efficacy of IBTROZI (taletrectinib) Across Key Patient Subgroups in Advanced ROS1+ NSCLC at 2026 World Conference on Lung Cancer Nuvation Bio Announces New Analyses Reinforcing the Durable, Consistent Efficacy of IBTROZI...

Jim Cramer: This Health Care Stock Is Pure Spec, The Only Neocloud I Like Is...

Cramer calls Nuvation Bio a pure spec, prefers CoreWeave over IREN, is unsure on Seneca, cautious on NuScale, and approves Box.read more...

Cramer's lightning round: Nuvation Bio 'is a pure spec'

"Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed...

Does Nuvation Bio (NUVB) Have the Potential to Rally 91.92% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 91.9% in Nuvation Bio (NUVB). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Nuvation Bio to Participate in Upcoming Investor Conferences

Nuvation Bio to Participate in Upcoming Investor Conferences Nuvation Bio to Participate in Upcoming Investor Conferences PR Newswire NEW YORK, Sept. 2, 2026 NEW YORK, Sept. 2, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest...

Nuvation Bio (NUVB) Upgraded to Buy: Here's Why

Nuvation Bio (NUVB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Nuvation Bio, Inc. is a biopharmaceutical company tackling some of the unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. The company was founded by David Hung on March 20, 2018 and is headquartered in New York, NY.

Nuvation Bio Inc - Ordinary Shares - Class A

NUVB Stock Is Soaring Today — Why RBC Sees $3B Opportunity In Nuvation Bio's Brain Cancer Drug

Equity

Bearish Sentiment

<ul class="summary-bullets"><li>Timashev said in the note that Nuvation Bio’s safusidenib continued to be more efficacious than the only approved therapy, vorasidenib, in low-grade glioma.</li><li>The analyst added that Nuvation Bio’s two planned studies could expand safusidenib's addressable market by targeting newly diagnosed and post-vorasidenib patients.</li><li>He said the approach positions the company to capture the "whole pie" of the IDH1-mutant glioma market, which RBC estimates could exceed $3 billion in peak sales.</li></ul>Nuvation Bio Inc. (NUVB) shares gained Monday after the company reported positive long-term data for its experimental brain cancer drug safusidenib, prompting RBC to highlight a potential market opportunity exceeding $3 billion.According to TheFly, RBC Capital analyst Leonid Timashev said the updated long-term follow-up data reinforce safusidenib's competitive profile in IDH1-mutant glioma.<a href="https://stocktwits.com/symbol/NUVB">Nuvation Bio shares</a> were up more than 9% in Monday morning’s trade. NUVB was among the top trending tickers on Stocktwits at the time of writing.<h2 class="st-heading-2">Why RBC Is Optimistic On NUVB’s Brain Cancer Drug</h2>Timashev said in the note that Nuvation Bio’s safusidenib continued to be more efficacious than the only approved therapy, vorasidenib, in low-grade glioma.The analyst added that Nuvation Bio’s two planned studies could expand safusidenib's addressable market by targeting newly diagnosed and post-vorasidenib patients.He said the approach positions the company to capture the "whole pie" of the IDH1-mutant glioma market, which RBC estimates could exceed $3 billion in peak sales.RBC maintained its ‘Outperform’ rating and $19 price target, adding that it expects investors to increasingly recognize the commercial opportunity surrounding safusidenib. RBC’s price target implies an upside potential of 202% from current levels.<h2 class="st-heading-2">NUVB’s Phase 2 Data</h2>Nuvation Bio reported updated Phase 2 data showing that safusidenib achieved a 51.9% confirmed objective response rate and a 79.1% progression-free survival rate at 36 months in patients with grade 2 IDH1-mutant glioma after a median follow-up of 38.8 months. The company reported no new safety signals.Alongside the updated data, Nuvation Bio expanded its clinical development program with two new studies: a Phase 3 trial in newly diagnosed grade 2 IDH1-mutant glioma patients outside the U.S., where vorasidenib is not yet approved or accessible, and a Phase 2 study in U.S. patients whose disease has progressed after treatment with vorasidenib.CEO David Hung said the expanded program is designed to evaluate safusidenib across a broader range of patients, with the goal of making it a treatment option for nearly every patient with IDH1-mutant glioma.“We continue to be very encouraged by the longer-term data from our Phase 2 J201 study, and today's announcement marks a pivotal step forward in our mission to bring safusidenib as a comprehensive treatment option for patients with all types of IDH1-mutant glioma,” Hung said.<h2 class="st-heading-2">Why IDH1-Mutant Glioma Matters</h2>Gliomas are the most common malignant primary brain tumors in adults. According to the Society for Neuro-Oncology consensus review published in the National Library of Medicine, IDH-mutant gliomas account for about 12% of glioma diagnoses in the U.S., and more than 90% harbor an IDH1 mutation.Nuvation Bio estimated that nearly 2,500 people in the U.S. are diagnosed with IDH-mutant glioma each year, with more than 95% of cases harboring an IDH1 mutation.Safusidenib is an investigational oral therapy designed to selectively inhibit mutant IDH1. Nuvation Bio is evaluating the drug across multiple clinical trials, including Phase 3 studies in newly diagnosed patients and a Phase 2 study in patients whose disease has progressed after treatment with vorasidenib.<h2 class="st-heading-2">What Retail Traders Think About NUVB</h2>Retail sentiment on Stocktwits around Nuvation Bio trended in the ‘neutral’ territory, with message volumes at ‘high’ levels at the time of writing.<a href="https://stocktwits.com/symbol/NUVB">NUVB stock</a> is down 30% year-to-date, but up 173% over the past 12 months. The iShares Russell 2000 ETF (IWM) is up 32% over the past 12 months, while the iShares Russell 2000 Growth ETF (IWO) is up 29%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/byron-deeter-chinese-ai-fears-misplaced-america-not-chase-fraction-pennies/cZZieqTR7ut">Byron Deeter Calls Fears About Chinese AI ‘Misplaced’ — Says Corporate&nbsp; America Is 'Not Going To Chase Fractions Of Pennies Per Token'</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

 In this photo illustration, the Nuvation Bio logo is seen displayed on the screen of a smart tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Nuvation Bio Inc. (NUVB) shares gained Monday after the company reported positive long-term data for its experimental brain cancer drug safusidenib, prompting RBC to highlight a potential market opportunity exceeding $3 billion.

According to TheFly, RBC Capital analyst Leonid Timashev said the updated long-term follow-up data reinforce safusidenib's competitive profile in IDH1-mutant glioma.

iShares Russell 2000 ETF

iShares Russell 2000 Growth ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$4.76
Prev Close	$4.77
Open	$4.75
Dividend Yield	0.00%
50-Day Moving Average	$5.63
Beta	1.63
Avg. Volume	4.76M
PE Ratio	-10.94

52-Week High	$9.75
52-Week Low	$3.92
Market Capitalization	$1.68B
EPS (Annual)	-$0.5991
Price to Book	6.56
Revenue Per Employee	$211,080.54

Feed

News

Sentiment

Earnings

Fundamentals

Info

NUVB Fundamentals